Creatine for Depression: Systematic Review Evidence and Clinical Mechanisms

A systematic review published in July 2026 examined the clinical evidence for creatine monohydrate as an adjunctive treatment for major depressive disorder. The analysis, covered by Technology Networks, synthesized data from controlled trials investigating whether supplementation with this well-characterized compound—primarily known for its muscle performance effects—affects depressive symptoms when added to standard pharmacotherapy. The review arrives as researchers increasingly recognize that depression involves disrupted brain energy metabolism, not solely neurotransmitter imbalance.

The question of creatine for depression is not speculative. Several placebo-controlled trials have now tested the hypothesis that restoring cerebral phosphocreatine levels may improve mood outcomes in patients with inadequate responses to conventional antidepressants. The evidence base remains small but mechanistically grounded: brain imaging studies consistently show reduced phosphocreatine and ATP in the prefrontal cortex and basal ganglia of depressed patients, suggesting that cellular energy deficits contribute to symptom persistence. This brief examines what the current research actually demonstrates, which populations showed benefit, and how creatine's known metabolic actions may intersect with depressive pathophysiology.

What Is Creatine?

Creatine is an endogenous compound synthesized in the liver and kidneys from the amino acids glycine, arginine, and methionine. It distributes throughout the body—skeletal muscle holds approximately 95% of total stores—where it serves as a rapidly mobilizable phosphate reservoir. The phosphocreatine system regenerates adenosine triphosphate (ATP) during high-demand intervals, buffering cellular energy availability when mitochondrial oxidative phosphorylation cannot keep pace. Dietary intake from meat and fish contributes 1–2 grams daily in omnivores; endogenous synthesis provides the remainder to maintain baseline stores of roughly 120 grams in a 70-kilogram adult.

The brain contains its own creatine pool, maintained by both local synthesis and uptake via the creatine transporter SLC6A8. Neurons and astrocytes use phosphocreatine to stabilize ATP levels during synaptic transmission, glutamate recycling, and ion homeostasis—processes that collectively account for the brain's disproportionate energy consumption relative to its mass. Genetic deficiencies in creatine synthesis or transport produce severe neurological phenotypes, including intellectual disability and seizures, underscoring the compound's necessity for normal brain function. Supplementation raises cerebral creatine and phosphocreatine concentrations by 5–15% in healthy adults, with larger increases observed in populations with lower baseline stores.

Creatine monohydrate—the form used in virtually all clinical research—consists of one creatine molecule bound to one water molecule. After oral ingestion, it dissociates in the stomach, and creatine is absorbed intact across the intestinal epithelium. Peak plasma concentration occurs 1–2 hours post-dose, followed by tissue uptake driven by sodium-dependent transporters. More than 1,000 clinical trials have characterized creatine monohydrate's effects across diverse physiological systems, establishing both its safety profile and the metabolic pathways through which it acts.

What Is Creatine Used For in Depression?

Creatine supplementation in the context of depression is investigated as an adjunctive intervention—added to ongoing antidepressant therapy rather than replacing it. The rationale stems from observations that standard antidepressants (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and others) achieve full remission in fewer than 40% of patients after initial treatment. A substantial proportion experience residual symptoms despite adequate pharmacotherapy, and some show minimal response to multiple medication trials. Targeting brain energy metabolism represents an orthogonal approach: if cellular ATP availability limits neuronal function in depression, restoring phosphocreatine stores may address a pathophysiological component that monoaminergic drugs do not reach.

Clinical applications of creatine for depression currently include:

• Augmentation of SSRI therapy in treatment-resistant depression: Controlled trials have tested daily creatine doses (typically 5 grams) added to stable SSRI regimens in patients who remained symptomatic after at least 8 weeks of antidepressant treatment.
• Support in adolescent and young adult depression: Preliminary evidence suggests benefit in females aged 13–21 with major depressive disorder, a population in whom cerebral creatine kinetics may differ from adults.
• Intervention in depression with cognitive symptoms: Studies targeting patients with prominent executive dysfunction or processing speed deficits, hypothesizing that prefrontal energy deficits contribute to both mood and cognitive symptoms.
• Adjunct in bipolar depression: Small open-label trials have explored creatine in bipolar disorder depression phases, given that mitochondrial dysfunction appears particularly pronounced in this population.

None of these applications constitute FDA-approved indications. Creatine remains an over-the-counter dietary supplement, and all depression treatment decisions require clinical oversight. The research examines whether supplementation adds measurable benefit to evidence-based psychiatric care, not whether creatine alone treats depression.

Evidence and Mechanisms

The clearest positive signal comes from a 2012 double-blind, placebo-controlled trial conducted by Kondo and colleagues. Fifty-two adolescent females (ages 13–21) with SSRI-resistant depression received either 5 grams daily of creatine monohydrate or placebo for 8 weeks, all while continuing their baseline antidepressant. The creatine group showed significantly greater reduction in Hamilton Depression Rating Scale (HDRS) scores compared to placebo, with mean score decreases of 9.3 versus 5.8 points (p = 0.007). Response rates—defined as ≥50% HDRS reduction—were 67% in the creatine group versus 35% with placebo. The effect emerged by week 2 and persisted through week 8, suggesting sustained impact rather than transient placebo response.

In adolescent females with treatment-resistant depression, 5 grams daily of creatine monohydrate added to SSRI therapy reduced depressive symptoms by 56% more than placebo over 8 weeks, with response rates doubling from 35% to 67%.

Brain imaging studies provide mechanistic context. Proton magnetic resonance spectroscopy (¹H-MRS) consistently demonstrates 5–10% reductions in prefrontal phosphocreatine and beta-nucleoside triphosphate (primarily ATP) in patients with major depression compared to healthy controls. These deficits correlate with symptom severity and normalize partially with successful treatment. Creatine supplementation increases brain phosphocreatine by 8–10% in healthy individuals and potentially more in those with baseline deficits, suggesting a restorative effect on cerebral energy reserves. The temporal match between phosphocreatine increases and clinical response supports causality rather than epiphenomenon.